i
SUPPLEMENTARY TABLE. Early Estimates of Updated 2023–2024 (monovalent XBB.1.5) COVID-19 Vaccine Effectiveness Against Symptomatic SARS-CoV-2 Infection Attributable to Co-circulating Omicron Variants Among Immunocompetent Adults — Increasing Community Access to Testing Program, United States, September 2023 – January 2024
-
02/01/2024
Details:
-
Corporate Authors:
-
Series:
-
Document Type:
-
Place as Subject:
-
Collection(s):
-
Main Document Checksum:
-
Download URL:
-
File Type: